Capricor Therapeutics announced that the Company presented the 18-month results from its HOPE-2 open-label extension study with lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy at this year’s Muscular Dystrophy Association Clinical & Scientific Conference, which took place virtually and in-person in Dallas, Texas from March 19-22, 2023. Dr. Craig McDonald, national Principal Investigator and University of California, Davis, Professor and Department of Physical Medicine and Rehabilitation Chair, presented the findings during a late-breaking session. Key results from the study, include: Statistically significant differences in the Performance of the Upper Limb scale in the CAP-1002 original treatment group when compared to the original placebo group from HOPE-2. Both groups experienced reduced disease progression once all patients began treatment in the OLE study. CAP-1002 treatment during the OLE portion of the study continues to yield a consistent safety profile and has been well-tolerated throughout the study. The HOPE-2 OLE study previously met the primary endpoint at the one-year time-point and these 18-month results suggest that patients accumulate benefit over time with preservation of skeletal muscle function, which underscore the potential long-term benefit of CAP-1002. Capricor is currently conducting the HOPE-3, Phase 3 trial, designed as a randomized, double-blind, placebo-controlled study with enrollment criteria similar to HOPE-2.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CAPR:
- Capricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
- Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15
- Capricor Therapeutics Receives Clinical Research Forum’s 2023 Top Ten Clinical Research Achievement Award
- Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan